BR112012017093A2 - compostos orgânicos para a regulação de canais de íons vetoriais - Google Patents

compostos orgânicos para a regulação de canais de íons vetoriais

Info

Publication number
BR112012017093A2
BR112012017093A2 BR112012017093A BR112012017093A BR112012017093A2 BR 112012017093 A2 BR112012017093 A2 BR 112012017093A2 BR 112012017093 A BR112012017093 A BR 112012017093A BR 112012017093 A BR112012017093 A BR 112012017093A BR 112012017093 A2 BR112012017093 A2 BR 112012017093A2
Authority
BR
Brazil
Prior art keywords
regulation
amino acid
ion channels
organic compounds
vector
Prior art date
Application number
BR112012017093A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernhard Fischer
Rudolf Lucas
Susan Tzostzos
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of BR112012017093A2 publication Critical patent/BR112012017093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012017093A 2010-01-14 2011-01-12 compostos orgânicos para a regulação de canais de íons vetoriais BR112012017093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0004110A AT509267A1 (de) 2010-01-14 2010-01-14 Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PCT/AT2011/000014 WO2011085423A1 (de) 2010-01-14 2011-01-12 Zyklische peptide zur regulierung von vektoriellen ionenkanälen

Publications (1)

Publication Number Publication Date
BR112012017093A2 true BR112012017093A2 (pt) 2016-11-29

Family

ID=43970939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017093A BR112012017093A2 (pt) 2010-01-14 2011-01-12 compostos orgânicos para a regulação de canais de íons vetoriais

Country Status (16)

Country Link
US (1) US8754049B2 (cg-RX-API-DMAC7.html)
EP (1) EP2523968B1 (cg-RX-API-DMAC7.html)
JP (1) JP5771220B2 (cg-RX-API-DMAC7.html)
KR (1) KR101865420B1 (cg-RX-API-DMAC7.html)
CN (1) CN102770442B (cg-RX-API-DMAC7.html)
AT (1) AT509267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011206907B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017093A2 (cg-RX-API-DMAC7.html)
CA (1) CA2785185C (cg-RX-API-DMAC7.html)
DK (1) DK2523968T3 (cg-RX-API-DMAC7.html)
ES (1) ES2525381T3 (cg-RX-API-DMAC7.html)
IL (1) IL220924B (cg-RX-API-DMAC7.html)
NZ (1) NZ600818A (cg-RX-API-DMAC7.html)
PL (1) PL2523968T3 (cg-RX-API-DMAC7.html)
RU (1) RU2538597C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011085423A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
AU2014257678A1 (en) * 2013-04-23 2015-10-15 Apeptico Forschung Und Entwicklung Gmbh Lyophilisate containing a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2
CN105188735A (zh) * 2013-04-23 2015-12-23 阿佩普蒂科研究和开发有限责任公司 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途
WO2015132294A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
EP3349779B1 (en) * 2015-09-14 2020-04-29 APEPTICO Forschung und Entwicklung GmbH Cyclic polypeptide for the treatment of pha type 1b

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére
FR2839514A1 (fr) * 2002-05-07 2003-11-14 Centre Nat Rech Scient Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens
CA2575513C (en) 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
CN101003520A (zh) * 2007-01-12 2007-07-25 陈志龙 一种缬氨酸丁酰联苯化合物
CN101007791A (zh) * 2007-01-12 2007-08-01 东华大学 一种氨基酸联苯化合物
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
CN101298432B (zh) * 2008-05-30 2010-12-22 广州市星业科技发展有限公司 L-吡咯烷酮羧酸钠的制备方法
ES2559840T3 (es) * 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
DK2397151T3 (en) * 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes

Also Published As

Publication number Publication date
CA2785185A1 (en) 2011-07-21
CN102770442A (zh) 2012-11-07
CN102770442B (zh) 2015-09-23
JP2013517224A (ja) 2013-05-16
EP2523968A1 (de) 2012-11-21
AT509267A1 (de) 2011-07-15
IL220924B (en) 2018-04-30
AU2011206907A1 (en) 2012-06-21
KR20120134100A (ko) 2012-12-11
PL2523968T3 (pl) 2015-03-31
JP5771220B2 (ja) 2015-08-26
AU2011206907B2 (en) 2016-06-02
KR101865420B1 (ko) 2018-07-13
CA2785185C (en) 2019-02-19
ES2525381T3 (es) 2014-12-23
RU2538597C2 (ru) 2015-01-10
US8754049B2 (en) 2014-06-17
RU2012134322A (ru) 2014-02-20
NZ600818A (en) 2014-02-28
DK2523968T3 (da) 2014-11-03
WO2011085423A1 (de) 2011-07-21
HK1174341A1 (en) 2013-06-07
US20130072444A1 (en) 2013-03-21
EP2523968B1 (de) 2014-09-10

Similar Documents

Publication Publication Date Title
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201591276A1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
EA202090053A3 (ru) Способы и композиции для лечения неэффективного эритропоэза
EA201390820A1 (ru) Слитый белок против рака
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
AR088392A1 (es) Macrociclos peptidomimeticos
EA201691146A1 (ru) Иммуногенное соединение
CR20160229A (es) Inhibidires de bromodominio
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA201000327A1 (ru) Белок
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201401211A1 (ru) Улучшенные варианты фермента химозина
EP3363458A3 (en) A peptide
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
CY1125043T1 (el) Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης
EA201591180A1 (ru) Составы ингибитора lfa-1
BR112015019412A2 (pt) inibidores de bace1
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
NZ700467A (en) Treatments suitable for malassezia infections

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]